KBC Group’s Nurix Therapeutics NRIX Stock Holding History

KBC Group’s Portfolio NRIX Stock Details NRIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$53K	Hold	2,192	–	–	﹤0.01%	1687
2026 Q1	$34K	Buy	+2,192	New	+$36.3K	﹤0.01%	1768

Other funds holding NRIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KBC Group's NRIX Position: Q2 2026 in Review

KBC Group held its Nurix Therapeutics (NRIX) position steady in Q2 2026 at 2,192 shares worth $53K. The position accounts for ﹤0.01% of the portfolio, ranked #1687.

KBC Group first reported a position in NRIX in Q1 2026 and has held it in 2 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

KBC Group held 2,192 shares of Nurix Therapeutics worth $53K as of Q2 2026.
KBC Group left its Nurix Therapeutics share count unchanged in Q2 2026.
Nurix Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1687 holding.
KBC Group first reported a position in Nurix Therapeutics in Q1 2026 and has held it in 2 quarters since.
212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.